Boston scientific receives fda approval for the agent™ drug-coated balloon

First coronary drug-coated balloon in u.s. provides safe, effective alternative to treat coronary in-stent restenosis and reduce risk of reoccurrence marlborough, mass. , march 1, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced it has received u.s. food and drug administration (fda) approval for the agent™ drug-coated balloon (dcb), which is indicated to treat coronary in-stent restenosis (isr) in patients with coronary artery disease.
BSX Ratings Summary
BSX Quant Ranking